ArticleCanadian respiratory journal2026
Clinical Prediction of Necrotizing Pneumonia in Children With Mycoplasma pneumoniae: A Model Based on Early Response to Therapy.
Article in Canadian respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Prediction of Necrotizing Pneumonia in Children With Mycoplasma pneumoniae: A Model Based on Early Response to Therapy.Canadian respiratory journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study aimed to identify factors that predict progression to necrotizing pneumonia (NP) in children with Mycoplasma pneumoniae pneumonia (MPP) who fail to respond to initial therapy and to develop a predictive model to support early clinical decision-making.
methodsWe retrospectively analyzed clinical and laboratory data of children with macrolide-unresponsive Mycoplasma pneumoniae pneumonia (MUMPP) admitted to Tianjin Children's Hospital from January 2021 to January 2025. MUMPP was defined as persistent fever (≥ 38.5°C, lasting ≥ 4 h/day) after ≥ 72 h of standardized intravenous macrolide therapy. Patients were classified into an observation group (n = 106, those who developed NP) and a control group (n = 130, those who did not). Independent predictors of NP were identified by multivariable logistic regression and incorporated into a nomogram. Model performance was evaluated using ROC analysis, calibration plots, and decision curve analysis.
resultsIn multivariable analysis, increased white blood cell (WBC) count (OR = 2.484, 95% CI: 1.406-4.613), longer fever duration (OR = 1.618, 95% CI: 1.217-2.193), pleural effusion (OR = 3.955, 95% CI: 1.664-10.00), and elevated C-reactive protein (CRP) (OR = 2.152, 95% CI: 1.547-3.074) were independently associated with NP among children with MPP after initial treatment failure. Calibration curves indicated close agreement between predicted and observed risks in both the derivation cohort (p = 0.588) and the validation cohort (p = 0.424). The model showed good discrimination, with an AUC of 0.848 (95% CI: 0.789-0.908) in the derivation cohort and 0.889 (95% CI: 0.815-0.963) in the validation cohort. Decision curve analysis suggested net clinical benefit across relevant threshold probabilities.
conclusionAmong children with MUMPP, higher WBC count, prolonged fever, pleural effusion, and higher CRP identify increased risk of NP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.